Evidence map›Paper›PMID 41079787›Full record

ReviewJournal of pharmaceutical analysis2025

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance.

Zhipeng Wang, Jie Wang, Dengxiong Li, Ruicheng Wu, Jianlin Huang, Luxia Ye, Zhouting Tuo, Qingxin Yu, Fanglin Shao, Dilinaer Wusiman and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhipeng WangDepartment of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Jie WangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Dengxiong LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Ruicheng WuDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jianlin HuangDepartment of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Luxia YeDepartment of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, 317000, China.
Zhouting TuoDepartment of Urological Surgery, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing, 400042, China.
Qingxin YuDepartment of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, Zhejiang, 315211, China.
Fanglin ShaoDepartment of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, Zhejiang, 646000, China.
Dilinaer WusimanDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, 999077, China.
Siang Boon KohFaculty of Health and Life Sciences, University of Bristol, Bristol, BS8 1TD, UK.
Wei XiongDepartment of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Dechao FengDivision of Surgery & Interventional Science, University College London, London W1W 7TS, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the most prevalent malignant tumor among men, ranking first in incidence and second in mortality globally. Novel hormone therapies (NHT) targeting the androgen receptor (AR) pathway have become the standard of care for metastatic prostate cancer. This review offers a comprehensive overview of NHT, including abiraterone, enzalutamide, apalutamide, darolutamide, and rezvilutamide, which have demonstrated efficacy in delaying disease progression and improving patient survival and quality of life. Nevertheless, resistance to NHT remains a critical challenge. The mechanisms underlying resistance are complex, involving

Indexed as

Advanced prostate cancerAndrogen receptorDrug resistanceNovel hormone therapies

Identifiers

PMID41079787
PMCPMC12512997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.